Bio Details

Gregory Perry

Board Member
Mr. Perry has served as Audit Committee Chair at Merus N.V. since 2016. He served as Chief Financial and Administrative Officer at Aegerion Pharmaceuticals Inc. from 2015 until the company’s merger with Novelion Therapeutics Inc., after which he served as Chief Financial and Administrative Officer at Novelion until December 2017. Prior to joining Aegerion, Mr. Perry held the role of Chief Financial and Business Officer at Eleven Biotherapeutics, Inc. from 2014-2015. He was a member of the Board of Directors, Audit Committee Chair and Compensation Committee Member at Ocata Therapeutics, Inc. from 2011 until the company was acquired by Astellas Pharma Inc. in 2016. Prior to that, he served as Senior Vice President and Chief Financial Officer at ImmunoGen, Inc. from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role that he held until 2013. From 2002-2008, Mr. Perry served as Chief Financial Officer at a series of biotechnology companies including Elixir Pharmaceuticals, Inc., Domantis Ltd. and Transkaryotic Therapies, Inc. Mr. Perry holds a Bachelor of Arts Degree in Economics and Political Science from Amherst College.
Financial Expert